The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | COMMANDS: luspatercept versus epoetin alfa in LR-MDS-associated anemia – results & caveats
Anand Patel, MD, University of Chicago, Chicago, IL, shares his perspectives on the findings of the Phase III COMMANDS study (NCT03682536) investigating the efficacy and safety of luspatercept versus epoetin alfa for the treatment of ESA-naive low-risk myelodysplastic syndromes (MDS)-associated transfusion-dependent anemia. Whilst overall, more patients taking luspatercept achieved the primary endpoint of a mean hemoglobin increase ≥1.5 g/dL, it appeared that patients who were ring sideroblast-negative benefited more from treatment with epoetin alfa. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
